Program
HY6725
A development code.
Its studies are led by Newsoara Biopharma.
Furthest: phase 1, since Nov 19, 20251 company-led study, 1 open or runningNext primary completion: Mar 2027 (phase 1)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Newsoara Biopharma | 11 open or running | phase 1since Nov 19, 2025 | Nov 19, 2025 | Mar 2027phase 1 · NCT07262281 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Nov 19, 2025First study: phase 1 study in HealthyFirst studyNCT07262281 · 74 planned · Australia
Ahead
- Mar 2027Primary completion: phase 1 study in HealthyNCT07262281
TargetBeta
“The rationale of the study is HY6725 is a novel, fully human monoclonal antibody engineered to simultaneously neutralize human TSLP and IL-33.”study text, by rule · the study
Other programs on the same two targets
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| HXN-1013rule | Helixon Biotechnology (Suzhou) | phase 1 | 1 |
Studies
All 1 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07262281Healthy · Australia | 1 | Recruiting | Mar 2027 | 74 |
How it is read
Names in the registry
- “HY6725”, 1 entry
Codes read as this program: HY6725.
Conditions, from the studies’ own filings
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.